Somatostatin analog and pegvisomant combination therapy for acromegaly.
about
Acromegaly and McCune-Albright syndrome.Optic neuropathy in McCune-Albright syndrome: effects of early diagnosis and treatment of growth hormone excessReduced brain somatostatin in mood disorders: a common pathophysiological substrate and drug target?Long-term results of fractionated stereotactic radiotherapy as third-line treatment in acromegaly.Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients.Inhibition of growth hormone receptor by Somavert reduces expression of GPER and prevents growth stimulation of triple-negative breast cancer by 17β-estradiol.
P2860
Somatostatin analog and pegvisomant combination therapy for acromegaly.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Somatostatin analog and pegvisomant combination therapy for acromegaly.
@en
Somatostatin analog and pegvisomant combination therapy for acromegaly.
@nl
type
label
Somatostatin analog and pegvisomant combination therapy for acromegaly.
@en
Somatostatin analog and pegvisomant combination therapy for acromegaly.
@nl
prefLabel
Somatostatin analog and pegvisomant combination therapy for acromegaly.
@en
Somatostatin analog and pegvisomant combination therapy for acromegaly.
@nl
P356
P1476
Somatostatin analog and pegvisomant combination therapy for acromegaly.
@en
P2093
Aart Jan van der Lely
Sebastian J C Neggers
P2888
P304
P356
10.1038/NRENDO.2009.175
P577
2009-10-01T00:00:00Z